Switch theme
Sign up to access all valuation multiples
Kusurinomadoguchi Inc is engaged in providing solutions for pharmacies and medical care..
2004
320
LTM Revenue n/a
LTM EBITDA n/a
$101M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Kusurinomadoguchi has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Kusurinomadoguchi achieved revenue of $58.0M and an EBITDA of $15.6M.
Kusurinomadoguchi expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Kusurinomadoguchi valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $49.3M | $58.0M | XXX | XXX | XXX |
| Gross Profit | $22.4M | $27.1M | XXX | XXX | XXX |
| Gross Margin | 45% | 47% | XXX | XXX | XXX |
| EBITDA | $11.2M | $15.6M | XXX | XXX | XXX |
| EBITDA Margin | 23% | 27% | XXX | XXX | XXX |
| Net Profit | $3.4M | $2.6M | XXX | XXX | XXX |
| Net Margin | 7% | 4% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 23, 2025, Kusurinomadoguchi's stock price is JPY 2247 (or $15).
Kusurinomadoguchi has current market cap of JPY 24.7B (or $164M), and EV of JPY 15.1B (or $101M).
See Kusurinomadoguchi trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $101M | $164M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 23, 2025, Kusurinomadoguchi has market cap of $164M and EV of $101M.
Kusurinomadoguchi's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Kusurinomadoguchi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Kusurinomadoguchi and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $101M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpKusurinomadoguchi's NTM/LTM revenue growth is n/a
Kusurinomadoguchi's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Kusurinomadoguchi's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Kusurinomadoguchi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Kusurinomadoguchi and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 18% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 40% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 41% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Alcidion Group | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Doctor Care Anywhere | XXX | XXX | XXX | XXX | XXX | XXX |
| Echo IQ | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kusurinomadoguchi acquired XXX companies to date.
Last acquisition by Kusurinomadoguchi was XXXXXXXX, XXXXX XXXXX XXXXXX . Kusurinomadoguchi acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Kusurinomadoguchi founded? | Kusurinomadoguchi was founded in 2004. |
| Where is Kusurinomadoguchi headquartered? | Kusurinomadoguchi is headquartered in Japan. |
| How many employees does Kusurinomadoguchi have? | As of today, Kusurinomadoguchi has 320 employees. |
| Is Kusurinomadoguchi publicy listed? | Yes, Kusurinomadoguchi is a public company listed on TKS. |
| What is the stock symbol of Kusurinomadoguchi? | Kusurinomadoguchi trades under 5592 ticker. |
| When did Kusurinomadoguchi go public? | Kusurinomadoguchi went public in 2023. |
| Who are competitors of Kusurinomadoguchi? | Similar companies to Kusurinomadoguchi include e.g. Benevolent AI, Alcidion Group, CurveBeam AI, Doctor Care Anywhere. |
| What is the current market cap of Kusurinomadoguchi? | Kusurinomadoguchi's current market cap is $164M |
| What is the current revenue growth of Kusurinomadoguchi? | Kusurinomadoguchi revenue growth between 2023 and 2024 was 18%. |
| Is Kusurinomadoguchi profitable? | Yes, Kusurinomadoguchi is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
